NCT01101581 2021-08-18Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLGilead SciencesPhase 1/2 Withdrawn
NCT00546793 2021-08-16Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLGilead SciencesPhase 1/2 Completed32 enrolled